Roivant Sciences Hits New 52-Week High at $30.30, Up 180.72%

Roivant Sciences has reached a significant milestone by hitting a new 52-week high of USD 30.30 on March 10, 2026. This achievement marks a remarkable increase of 180.72% over the past year, significantly outperforming the S&P 500, which has seen a gain of 20.78% during the same period. As a mid-cap company in the Pharmaceuticals & Biotechnology sector, Roivant Sciences has a market capitalization of approximately USD 19,431 million. Despite its impressive stock performance, the company is currently loss-making, reflected in its P/E ratio, which is not applicable. The stock also has a price-to-book ratio of 4.55, indicating its valuation relative to its net assets. Additionally, Roivant Sciences has a debt-to-equity ratio of -1.06 and a return on equity of -26.15%, highlighting its financial structure and performance metrics. The company does not offer a dividend yield, which is consistent with its focus on growth and reinvestment in its operations. This recent price movement underscores the dynamic nature of the stock and its position within the market.